Background：Wee1 is a protein kinase that inhibits cyclin-dependent kinase 1 and 2 (CDK1/2), thereby activating the G2/M cell cycle checkpoint, causing cell cycle arrest and providing time for DNA damage repair. Inhibition of Wee1 prevents G2/M checkpoint initiation, leading to unscheduled mitotic entry with less precisely repaired DNA damage, subsequent loss of genomic integrity. Given the key role of p53 in the regulation of G1 checkpoint and the increased reliance on the G2/M checkpoint in p53-deficient cells, there is a strong biological rational supporting targeting p53-deficient tumor with Wee1 inhibitor.
Description：Impact has built the most comprehensive DNA damage response (DDR) product pipeline among biotech companies globally. IMP7068 is a novel chemical entity targeting Wee1, a scientifically validated DDR target. Impact designed the molecule with higher selectivity and lower toxicity that allow potential for internal and external combination. IMP7068 is undergoing IND enabling studies.